Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DWC202313
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
DWC202313 is an investigational pharmaceutical agent currently being studied primarily for the treatment of essential hypertension. It is being evaluated in combination with other agents (such as DWC202405 and DWC202314) in multi-center, randomized, double-blind Phase III clinical trials to assess its efficacy and safety in patients whose hypertension is inadequately controlled by existing therapies. The drug has also been involved in Phase I studies examining its pharmacokinetic interactions with other investigational compounds. The precise mechanism of action, molecular target, chemical class, and developer have not been disclosed in publicly available sources[3][5].
Beyond the preview
Go deeper on DWC202313.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DWC202313.